University of California, Irvine
Orange, California
Dr. Tewari is a Professor and Division Director of Gynecologic Oncology at the University of California, Irvine where he holds the Philip J. DiSaia, MD Endowed Chair in Gynecologic Oncology. He has focused his career on the development of therapeutics for women strugging with cervical cancer. Dr. Tewari was the Principal Investigator and Study Chair for Gynecologic Oncology Group protocol 240 which was funded by the National Cancer Institute (NCT00803062). GOG-0240 is the practice-changing phase 3 randomized trial that demonstrated a statistically significant and clinically meaningful benefit with the incorporation of anti-angiogenesis therapy using Bevacizumab for first-line treatment of advanced cervical cancer (Tewari KS, et al. N Engl J Med 2014 and Tewari KS, et al Lancet 2017). This single trial fulfilled an unmet clinical need and led directly to US FDA approval of Bevacizumab for cervical cervical cancer as well as regulatory approval in the European Union and at least sixty other countries. Dr. Tewari followed this work with the EMPOWER phase 3 randomized trial (NCT03257267) studying the anti-PD1 immunologic checkpoint inhibitor Cemiplimab as a second-line monotherapy for recurrent cervical cancer (Tewari KS, et al N Engl J Med 2022). EMPOWER is the first randomized randomized trial demonstrating a survival benefit using immunotherapy in recurrent cervical cancer. Finally, Dr. Tewari was a co-investigator for the practice-changing KeyNote-826 phase 3 randomized trial (NCT03635567) which moved immunotherapy using the anti-PD1 checkpoint inhibitor Pembrolizumab into the first-line for recurrent/metastatic cervical cancer (Colombo N, …Tewari KS, et al. N Engl J Med 2021).
Session 2: Management of Metastatic/Recurrent Cervical Cancer in the Front Line
Wednesday, May 3, 2023
9:15 AM – 9:50 AM ET
Wednesday, May 3, 2023
9:50 AM – 10:00 AM ET